Skip to main content

Safety Issues

20
Pipeline Programs
23
Companies
32
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
14
0
2
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
480%
Small Molecule
120%
+ 29 programs with unclassified modality

Competitive Landscape

22 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
13 programs
5
2
1
3
Diphtheria AntitoxinPhase 41 trial
Enoxaparin sodium injectionPhase 41 trial
Measles-RubellaPhase 41 trial
Vi-DT Typhoid Conjugate VaccinePhase 3Vaccine1 trial
Quadrivalent Influenza VaccinePhase 2Vaccine1 trial
+8 more programs
Active Trials
NCT05037227Completed1,100Est. Dec 2021
NCT04268758Withdrawn0Est. Dec 2021
NCT04485481Completed42Est. Jan 2022
+10 more trials
AyuVis Research
AyuVis ResearchTX - Fort Worth
1 program
1
AVR-48Phase 11 trial
Active Trials
NCT06847698Not Yet Recruiting48Est. Nov 2025
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
EXT608Phase 11 trial
Active Trials
NCT05408663Completed24Est. Jun 2023
Kariya Pharmaceuticals
Kariya PharmaceuticalsDenmark - Copenhagen
1 program
1
KP405Phase 11 trial
Active Trials
NCT06189170Recruiting88Est. Mar 2026
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
MVA-BN-Brachyury/ FPV-BrachyuryPhase 1
Paion
PaionGermany - Aachen
1 program
1
RemimazolamPhase 11 trial
Active Trials
NCT04113343Completed21Est. Aug 2017
SPARK Biopharma
SPARK BiopharmaKorea - Seoul
1 program
1
SB17170Phase 11 trial
Active Trials
NCT05795192Completed64Est. Mar 2024
Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
SSS55Phase 11 trial
Active Trials
NCT07058779Recruiting26Est. Dec 2027
Zenshine Pharmaceuticals
1 program
1
ZX-7101APhase 11 trial
Active Trials
NCT05217732Completed66Est. Dec 2022
Aosaikang Pharmaceutical
1 program
1
dexlansoprazolePhase 1Small Molecule2 trials
Active Trials
NCT03120273Unknown70Est. Sep 2017
NCT03011125Completed28Est. Mar 2017
Cerus
CerusCA - Concord
1 program
Amustaline/GSH pathogen reduction technologyN/A1 trial
Active Trials
NCT04020224Withdrawn0Est. Mar 2025
BlueSky Immunotherapies
BlueSky ImmunotherapiesAustria - Vienna
1 program
Observation without interventionN/A1 trial
Active Trials
NCT04528407Completed25Est. Jan 2025
Sigrid Therapeutics
Sigrid TherapeuticsSweden - Stockholm
1 program
Porous silicaN/A1 trial
Active Trials
NCT03667430Completed20Est. Feb 2016
Neurovalens
NeurovalensUK - Belfast
1 program
Vestal DMN/A1 trial
Active Trials
NCT04783883Completed25Est. Jul 2021
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
paclitaxel-coated balloon angioplasty or bare mental stents implantationN/A1 trial
Active Trials
NCT05517291Recruiting200Est. Dec 2027
Q32 Bio
Q32 BioMA - Waltham
1 program
ADX-914PHASE_1
Vicore Pharma
Vicore PharmaSweden - Stockholm
1 program
C106 solutionPHASE_11 trial
Active Trials
NCT05427253Completed80Est. Jun 2023
Cerevance
CerevanceMA - Boston
1 program
CVN766PHASE_11 trial
Active Trials
NCT05105243Completed64Est. Nov 2022
Gossamer Bio
Gossamer BioCA - San Diego
1 program
GB002PHASE_1
Nxera Pharma
Nxera PharmaJapan - Tokyo
1 program
HTL0018318PHASE_11 trial
Active Trials
NCT03198624Completed54Est. Aug 2017
Cinclus Pharma
Cinclus PharmaSweden - Stockholm
1 program
Linaprazan gluratePHASE_11 trial
Active Trials
NCT05633147Completed35Est. May 2023
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
MVA-BN-Brachyury/ FPV-BrachyuryPHASE_11 trial
Active Trials
NCT03349983Completed11Est. Jun 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BiocorpEnoxaparin sodium injection
BiocorpDiphtheria Antitoxin
BiocorpMeasles-Rubella
BiocorpVi-DT Typhoid Conjugate Vaccine
BiocorpVi-DT Vaccine
BiocorpQuadrivalent Influenza Vaccine
Sunshine BiopharmaSSS55
AyuVis ResearchAVR-48
Kariya PharmaceuticalsKP405
BiocorpOmniMSC-AMI
SPARK BiopharmaSB17170
Cinclus PharmaLinaprazan glurate
Integrated BiosciencesEXT608
Vicore PharmaC106 solution
CerevanceCVN766

Showing 15 of 32 trials with date data

Clinical Trials (32)

Total enrollment: 7,726 patients across 32 trials

NCT06114641BiocorpEnoxaparin sodium injection

Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients

Start: Jun 2023Est. completion: Aug 2024220 patients
Phase 4Completed
NCT06053853BiocorpDiphtheria Antitoxin

Post Marketing Surveillance of Diphtheria Antitoxin (DAT)

Start: Jan 2023Est. completion: May 202368 patients
Phase 4Completed
NCT03680417BiocorpMeasles-Rubella

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

Start: Nov 2017Est. completion: Aug 2018590 patients
Phase 4Completed
NCT04051268BiocorpVi-DT Typhoid Conjugate Vaccine

Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

Start: Mar 2020Est. completion: Dec 20213,071 patients
Phase 3Completed
NCT03460405BiocorpVi-DT Vaccine

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

Start: Jul 2018Est. completion: Jan 2020600 patients
Phase 2Completed
NCT03336593BiocorpQuadrivalent Influenza Vaccine

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Start: Nov 2017Est. completion: Nov 2018810 patients
Phase 2Completed

Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

Start: Aug 2025Est. completion: Dec 202726 patients
Phase 1Recruiting

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

Start: Jun 2025Est. completion: Nov 202548 patients
Phase 1Not Yet Recruiting

Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

Start: Aug 2024Est. completion: Mar 202688 patients
Phase 1Recruiting

Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients

Start: Jun 2023Est. completion: Mar 202610 patients
Phase 1Recruiting

SB17170 Phase1 Trial in Healthy Volunteer

Start: May 2023Est. completion: Mar 202464 patients
Phase 1Completed
NCT05633147Cinclus PharmaLinaprazan glurate

Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam

Start: Nov 2022Est. completion: May 202335 patients
Phase 1Completed

A Phase 1 Study of EXT608 in Healthy Adults

Start: Jul 2022Est. completion: Jun 202324 patients
Phase 1Completed

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Start: Jun 2022Est. completion: Jun 202380 patients
Phase 1Completed

Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers

Start: Jan 2022Est. completion: Nov 202264 patients
Phase 1Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Start: Dec 2021Est. completion: Dec 202266 patients
Phase 1Completed

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

Start: Sep 2020Est. completion: Jan 202242 patients
Phase 1Completed

Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates

Start: Apr 2018Est. completion: Mar 2019100 patients
Phase 1Completed
NCT03349983Bavarian NordicMVA-BN-Brachyury/ FPV-Brachyury

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

Start: Jan 2018Est. completion: Jun 202011 patients
Phase 1Completed

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

Start: Sep 2017Est. completion: Dec 201866 patients
Phase 1Completed
NCT04113343PaionRemimazolam

Oral Remimazolam With and Without Alcohol in Healthy Female Subjects

Start: May 2017Est. completion: Aug 201721 patients
Phase 1Completed

Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects

Start: May 2017Est. completion: Aug 201754 patients
Phase 1Completed

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults(Part 2)

Start: May 2017Est. completion: Sep 201770 patients
Phase 1Unknown

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

Start: Apr 2017Est. completion: Feb 2018100 patients
Phase 1Completed

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)

Start: Jan 2017Est. completion: Mar 201728 patients
Phase 1Completed
NCT04020224CerusAmustaline/GSH pathogen reduction technology

INTERCEPT Safety Evaluation on Whole Blood

Start: Jan 2024Est. completion: Mar 20250
N/AWithdrawn
NCT05517291UNION therapeuticspaclitaxel-coated balloon angioplasty or bare mental stents implantation

DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease

Start: Sep 2022Est. completion: Dec 2027200 patients
N/ARecruiting
NCT05037227BiocorpSafety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia

Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia

Start: Sep 2021Est. completion: Dec 20211,100 patients
N/ACompleted

A Single-center Study Designed to Evaluate the Safety and Efficacy of Tulipon

Start: Jun 2021Est. completion: Dec 20210
N/AWithdrawn
NCT04528407BlueSky ImmunotherapiesObservation without intervention

BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects

Start: Apr 2021Est. completion: Jan 202525 patients
N/ACompleted

Electrical Vestibular Nerve Stimulation (VeNS): A Follow-up Assessment of Long-term Usage

Start: Mar 2021Est. completion: Jul 202125 patients
N/ACompleted

Safety Evaluation of Porous Silica in Men

Start: Sep 2015Est. completion: Feb 201620 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 7,726 patients
23 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.